177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Key facts

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Principal Investigator

Giovanni Paganelli, MD

IRST IRCCS, Meldola (FC)

Intervention

Capecitabine(drug)

Enrollment

35 enrolled

Eligibility

19 years · All sexes

Timeline

2016 – 2023

Study locations (1)

• Irst Irccs, Meldola, FC, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroendocrine neoplasm of pancreas

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06246630
  In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
  Ruijin Hospital
• RECRUITINGNANCT05243082
  Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
  Oslo University Hospital

See all trials for Neuroendocrine neoplasm of pancreas →